Prof. Libby gives an introduction to the symposium about the evolving role of triglycerides in residual CV risk, that was held during the virtual ESC 2020 congress.
Prof. Bhatt gives a recap of the findings of the main REDUCE-IT trial with icosapent ethyl and of subsequent analyses.
In patients with dyslipidemia, levels of apoB-containing lipoproteins are elevated, containing both triglycerides and cholesterol. What are the treatment targets of these non-LDL-c parameters and how can these be achieved?
What is the role of triglyceride-rich lipoproteins in residual risk in patients with ASCVD?
Expert discussion on novel opportunities tackling residual cardiovascular risk: The evolving role of triglycerides.